Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Study identifier:MB001-078

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Medical condition

Diabetes mellitus type 2

Phase

-

Healthy volunteers

No

Study drug

Exenatide

Sex

All

Actual Enrollment

1711

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Feb 2009
Primary Completion Date: 01 Mar 2014
Study Completion Date: 01 Mar 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria